SCHEMBL8529005

SCHEMBL8529005

COC(=O)CNC(=O)c1c(Cl)cc(CCc2ccccc2)n2ncnc12

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 12/20 0.47
BBOX1 O75936 1/20 0.42
ASPH Q12797 1/20 0.42
KDM8 Q8N371 1/20 0.42
EGLN3 Q9H6Z9 2/20 0.40
VEGFA P15692 1/20 0.40
FLT1 P17948 1/20 0.40
PKM P14618 2/20 0.39
GLA P06280 1/20 0.39
NAPEPLD Q6IQ20 1/20 0.39
TAAR1 Q96RJ0 1/20 0.37
HPGD P15428 1/20 0.37
XDH P47989 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8520898 0.86 EGLN1 (0.42) EGLN1PKM
SCHEMBL8520900 0.82 EGLN1 (0.43) EGLN1BBOX1ASPHKDM8
Hydrochloric Acid SCHEMBL21403277 0.81 EGLN1 (0.44) EGLN1BBOX1ASPHKDM8
SCHEMBL12828564 0.81 EGLN1 (0.50) EGLN1BBOX1ASPHKDM8HPGD
SCHEMBL21403271 0.79 EGLN1 (0.41) EGLN1BBOX1ASPHKDM8
Enarodustat SCHEMBL1481440 0.79 EGLN1 (0.64) EGLN1BBOX1ASPHKDM8EGLN3
Enarodustat SCHEMBL21403279 0.78 EGLN1 (0.63) EGLN1BBOX1ASPHKDM8EGLN3
Enarodustat SCHEMBL1481939 0.78 EGLN1 (0.65) EGLN1BBOX1ASPHKDM8EGLN3
SCHEMBL8527866 0.76 EGLN1 (0.47) EGLN1BBOX1ASPHKDM8HPGD
Enarodustat SCHEMBL21403278 0.76 EGLN1 (0.53) EGLN1BBOX1ASPHKDM8EGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036723-A Enalidomide Key intermediate and application thereof 迪嘉药业集团股份有限公司 2026-05-15 CN disclosed
US-11434238-B2 Method for producing triazolopyridine compound JAPAN TOBACCO INC. (JP) 2022-09-06 US disclosed
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND SHIONOGI & CO., LTD. (JP) 2020-10-29 US disclosed
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND SHIONOGI & CO., LTD. (JP) 2020-10-29 US disclosed
EP-3546459-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND Japan Tobacco, Inc. (JP) 2019-10-02 EP disclosed
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2016-05-26 US disclosed
EP-2455381-B9 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-10-22 EP disclosed
EP-2455381-B1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER JAPAN TOBACCO INC (JP) 2014-05-28 EP disclosed
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2013-04-18 US disclosed
US-8283465-B2 Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent JAPAN TOBACCO INC. (JP) 2012-10-09 US disclosed
EP-2455381-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER Japan Tobacco, Inc. (JP) 2012-05-23 EP disclosed
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT JAPAN TOBACCO INC. (JP) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339563-A1 METHOD FOR PRODUCING TRIAZOLOPYRIDINE COMPOUND EPOR, PAH, THPO EGLN1 13/4885BBOX1 2638/4885ASPH 1932/4885
US-20130096155-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885BBOX1 1541/4885ASPH 39/4885
US-11434238-B2 Method for producing triazolopyridine compound EPOR, PAH, THPO EGLN1 13/4885BBOX1 2638/4885ASPH 1932/4885
US-20110077267-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885BBOX1 1541/4885ASPH 39/4885
US-20160145254-A1 TRIAZOLOPYRIDINE COMPOUND, AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR OR ERYTHROPOIETIN PRODUCTION-INDUCING AGENT EGLN3, EPOR, EGLN2 EGLN1 8/4885BBOX1 1541/4885ASPH 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.